Clinical trial NCT02576821: Hippocampal Sclerosis and Amnesia Not Due to Alzheimer's Disease
Official title: Hippocampal Sclerosis and Amnesia Not Due to Alzheimer's Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Patients With Cognitive Disturbances
Keywords: Amnesia, Alzheimer, hippocampal sclerosis, fronto-temporal lobar degeneration
Lead sponsor: Centre Hospitalier St Anne
Sponsor class: OTHER
First posted: 2015-10-15
Enrollment: 141
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Hippocampal Sclerosis (HS) leads to anterograde amnesia mimicking early Alzheimer's disease (AD) (so called HSA-nonAD). Recent studies showed that (a) the deficit of episodic memory as well as the level of hippocampal atrophy in bvFTD may be of similar severity to that observed in AD, even at initial presentation, leading to misdiagnosis in 22% of cases with post mortem diagnosis; (b) amnesia with HS due to microvascular lesion and microinfarcts can also cause impairment of episodic memory mimicking AD, without subcortical cognitive profile. Because these diseases involve distinct pathophysiological processes, they require different specific care and treatment. In consequence, it is very important to improve our knowledge about HS in order to identify its mechanism and improve the diagnosis.

Detailed description: Hippocampal sclerosis (HS) refers to neuronal cell loss and astrocytosis in subiculum and cornu ammonis subfields of the hippocampal formation unrelated to Alzheimer's disease pathology. In contrast to HS that affects younger adults with epilepsy, older individuals with HS have significant ante-mortem cognitive dysfunction but no epilepsy. Neuropathological studies demonstrated three main types of HS associated with aging: (a) HS-Ageing to refer to the disease with HS pathology in ageing individuals, observed in more than 10% of subjects aged over 85 years; (b) HS observed in the behavioural variant of frontotemporal dementia (bvFTD), HS being more frequent in tau-negative pathology, especially in FTLD-TDP. bvFTD patients may manifest severe episodic memory impairment and hippocampal atrophy; (c) HS associated with cortical or subcortical cerebral microinfarcts, which are invisible on conventional MRI. Cerebral microinfarcts are observed in 33% of elderly over 85 years in post-mortem studies.

HS leads to anterograde amnesia mimicking early Alzheimer's disease (AD) (so called HSA-nonAD). Recent studies showed that (a) the deficit of episodic memory as well as the level of hippocampal atrophy in bvFTD may be of similar severity to that observed in AD, even at initial presentation, leading to misdiagnosis in 22% of cases with post mortem diagnosis; (b) amnesia with HS due to microvascular lesion and microinfarcts can also cause impairment of episodic memory mimicking AD, without subcortical cognitive profile. Because these diseases involve distinct pathophysiological processes, they require different specific care and treatment. In consequence, it is very important to improve our knowledge about HS in order to identify its mechanism and improve the diagnosis.

Eligibility criteria: Inclusion Criteria:

General inclusion criteria

* Be older than18 years old.
* Consulting in one of the centers (patients only)
* Sufficient cognitive capacities for the realization of the clinical and neuropsychological evaluations, left to the judgement by the investigator.
* Women old enough to procreate under effective contraception
* Signed consent
* Absence of general or systemic disorders that may interfere with cognition.
* If available before inclusion, absence of brain lesions as determined by MRI that may account for even part of the clinical presentation.

Patients with Hippocampal sclerosis non AD (n=40)

Clinical criteria :

* CDR (Clinical Dementia Rating Scale) = 0.5 or 1
* Progressive amnestic syndrome of the hippocampal type, defined by a free recall score ≤ 17/48 and a total recall score ≤ 40/48 on the FCSRT.

Biological criteria : Absence of Profile suggestive of AD on the study of the biomarkers of the CSF (IATI ratio \> 0.8)

Patients with Alheimer's Disase (n=40)

Clinical criteria :

* CDR (Clinical Dementia Rating Scale) = 0.5 or 1
* Typical amnesic AD : Progressive amnestic syndrome of the hippocampal type, defined by a free recall score ≤ 17/48 and a total recall score ≤ 40/48 on the FCSRT, associated or not with others cognitive impairment
* Posterior Cortical Atrophy : initial presentation of progressive visual or visuospatial impairment; absence of ophthalmologic impairment with evidence of complex visual and/or visuospatial disorder on examination; a relatively preserved episodic memory
* Logopenic progressive aphasia : word retrieval deficits in spontaneous speech and confrontation naming, impaired repetition of sentences, errors in spontaneous speech and naming (eg, phonological errors), and relative sparing of word and object knowledge and motor speech.

Biological criteria : CSF biomarkers suggestive of AD defined on CSF.

Patients with DLFT (n=20) :

Clinical criteria :

* Modifications of the personality and the social conducts in the foreground
* Compatible brain imaging with the diagnosis : profile of atrophy and/or hypometabolism in TEP-FDG (or hypoerfusion in Spect) compatible with the diagnosis of DFT and/or absence of atypie Biological criteria : No AD profile on CSF biomarkers

Patients with CBD/PSP (n=20) (Armstrong et al., 2013)

1. Corticobasal syndrome :

   * at least one of the following signs : limb rigidity or akinesia, limb dystonia, limb myoclonusplus at least one of the following sign : orobuccal or limb apraxia, e) cortical sensory deficit, alien limb phenomena (more than simple levitation)
   * Nonfluent/agrammatic variant of primary progressive aphasia: Effortful, agrammatic speech plus at least one of: a) impaired grammar/sentence comprehension with relatively preserved, single word comprehension, or b) groping, distorted speech production (apraxia of speech)
2. Progressive supranuclear palsy syndrome :

   * Three of the following items present: a) axial or symmetric limb rigidity or akinesia, b) postural instability or falls, c) urinary incontinence, d) behavioural changes, e) supranuclear vertical gaze palsy or decreased velocity of vertical saccades

Normal controls (n=20):

Absence of known psychiatric disorder Score on the Folstein Mini Mental Status (MMSE \> or = 27) Normal neuropsychological assessment for the age and the educational level

Exclusion Criteria:

* Subject with a psychiatric evolutionary and/or badly checked pathology (left to the judgement of the investigator).
* Subject with a grave, severe or unstable pathology (left to the judgement of the investigator) the nature of which can interfere with the variables of evaluation.
* Epileptics subjects, badly tolerant MRI (1.5T, 3T or 7T), Subject presenting contraindications to the MRI (if necessary, a blood pregnancy test will be performed before 7T MRI) (Pacemaker or stimulating neurosensory or implantable defibrillator, cochlear implants, eye or cerebral ferromagnetic foreign bodies close to nervous structures, metallic prostheses, agitation of the patient : not cooperative or agitated patients, very young children, claustrophobics subjects, pregnant women, neurosurgical ventriculoperitoneal shunt valves, brace)
* Known or supposed histories (\< or = 5 years) of severe alcoholism or misuse of drugs
* Vascular, inflammatory or expansive, visible lesion in the MRI which can interfere on the criteria of diagnosis.
* No health insurance
* Pregnant, breast-feeding woman or planning a pregnancy in two years of follow-up.
* For controls : anomaly detected on the MRI in the appreciation of the investigator

Primary outcomes:
measure: 7 tesla MRI.
timeFrame: up to Month 18
Secondary outcomes:
measure: 3T MRI
timeFrame: Baseline
measure: 3T MRI
timeFrame: Month 12
measure: 3T MRI
timeFrame: Month 24
measure: 3T MRI
timeFrame: Baseline
measure: 3T MRI
timeFrame: Month 12
measure: 3T MRI
timeFrame: Month 24
measure: 7T MRI
timeFrame: up to Month 18
measure: CSF
timeFrame: Baseline
measure: Neuropsychological assessment
timeFrame: Baseline
measure: Neuropsychological assessment
timeFrame: Month 12
measure: Neuropsychological assessment
timeFrame: Month 24
measure: Clinical assessment
timeFrame: M0
measure: Clinical assessment
timeFrame: Month 12
measure: Clinical assessment
timeFrame: Month 24
measure: Genetic markers of bvFTD
timeFrame: Baseline
measure: Blood markers
timeFrame: Baseline
measure: Plasmatic progranulin levels
timeFrame: Baseline
measure: Regional glucose hypometabolism
timeFrame: Baseline
Other outcomes:
Locations:
city: Paris
country: France
facility: Neurologie de la mémoire et du langage, Service de Neurologie, Centre Hospitalier Sainte-Anne
Study officials:
affiliation: Centre Hospitalier Sainte-Anne
name: Marie SARAZIN, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: